D

Dynavax Technologies Corp
D

DVAX

13.335
USD
0.00
(0.00%)
مغلق
حجم التداول
84,165
الربح لكل سهم
0
العائد الربحي
-
P/E
89
حجم السوق
1,752,946,571
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    B
    BCRX
    -0.17000
    (-1.81%)
    9.20000 USD
    E
    EBS
    -0.12000
    (-1.53%)
    7.72000 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    I
    INO
    0.02000
    (0.91%)
    2.23000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    S
    SVA
    0
    (0.00%)
    0 USD
    TAK
    TAK
    0.210
    (1.52%)
    14.060 USD
    V
    VSTM
    0.11500
    (2.06%)
    5.68500 USD
    المزيد
الأخبار
المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.